Bioreactor Market Size Worth Over $470mn By 2023: Fermentor

Bioreactor market size is estimated to exceed USD 470 million by 2023 and is likely to grow at a CAGR of over 18% from 2016 to 2023.

Low operational cost accompanied by minor requirement for maintenance and monitoring compared to traditional ones is anticipated to drive industry demand. In addition, low energy consumption coupled with simplicity in culturing of marine microorganism namely algae is likely to propel the industry demand for this system over the several forthcoming years. Single use bioreactor market size is likely to exceed USD 500 million by 2023.

Intense growth potential of biologics industry is likely to offer massive growth avenues to the industry participants over the forecast period. Furthermore, lack of availability of sterilized sensors is anticipated to hider the industry growth. Low volume capacity of these systems is likely to challenge the industry demand for bioreactors from 2016 to 2023.

Bioreactor manufacturer

fermentation tank

GMP Fermentation system

The bioreactor market can be segmented on the basis of product, molecule, cell, technology and end use. On the basis of product type it can be segregated as recombinant proteins and monoclonal antibodies. Based on cell type, the industry can be segmented into bacteria, mammalian cells as well as yeast. Mammalian cells are anticipated to be the fastest and largest growing in the industry. The spur can be subjected to higher effectiveness of biomolecules exhibited by mammalian cells.

On the basis of technology the industry can be segmented into wave-induced motion SUB, stirred SUB and single use bubble column bioreactor. Wave-induced motion SUB sector is anticipated to account for the major share and is expected to grow at the highest rate over the forecast period. On the basis of molecule the industry can be segregated into vaccines, monoclonal antibodies (MAbs), gene therapy, recombinant proteins and stem cells. Based on end user the industry can be segmented as R&D department and bio pharmaceutical manufacturers. R&D can be further segregated into biopharmaceutical manufacturers, CROs and research institutes.

Vendors are anticipated to expand the range of options offered along with the flexibility of systems, facilitating users to experiment with different amalgamations of bioprocessing components. Proliferating R&D through commercial production and pilot-scale, mixing & matching systems in order to find the best solution for a particular application is expected to fuel the industry over the several upcoming years.

Bioreactors that contain disposable bags are proficiently used in the medical sector instead of the ones with culture vessel made of glass or stainless steel. As pharmaceutical companies manufacture diverse drugs using the same facility without negotiating the quality of the product produced and thus operates in various successive batches. For such scenarios, the disposable bioreactors are the preferred ones. As these reactors does not require any additional sterilization or cleaning work.

Portable bioreactor from MIT produces medications, vaccines on-demand

Imagine a cross between one of those multi-color retractable pens and an epi-pen. But instead of colors, the device would have different medications. Now combine this with a tiny, droplet-sized sweatshop full of obedient single-celled organisms genetically engineered to produce those medications, and you've got what a team from MIT just published in Nature Communications: A new project, with funding from DARPA, that has demonstrated the ability to synthesize multiple medications on-demand and as-needed using yeast. The discovery could soon revolutionize our ability to deliver medicine after natural disasters or to remote locations.

scale up bioreactor

scale down bioreactor

small scale bioreactor

Let's stick with the metaphor of an epi-pen. First, the user presses the actuator, which mixes a chemical trigger into a culture of engineered Pichia pastoris cells. Upon exposure to certain chemical triggers, the cells are programmed to produce a protein: in the report, the team used estrogen β-estradiol, which caused the cells to express recombinant human growth hormone (rHGH), and also methanol, which induced the same culture of yeast to make interferon. By controlling the concentration of the chemical trigger and the population of P. pastoris, the team demonstrated that they could make their device produce a dose of either interferon or rHGH on command. To switch between products, they just pushed another button on the microbioreactor, which flushes out the cell culture with clean, sterile fluid.